Skip to Main Content

Author Details

Philip Wong
Princess Margaret Cancer Centre, University Health Network
2002
45
17
PMIDPaper TitleJournal TitlePublished Year
37971410The Use of Wearable Devices in Oncology Patients: A Systematic Review.Oncologist2024
36309074Evaluating the Short-term Environmental and Clinical Effects of a Radiation Oncology Department's Response to the COVID-19 Pandemic.Int J Radiat Oncol Biol Phys2023
37025758Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases.Neurooncol Adv2023
35243022<b>S</b>tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC).Clin Transl Radiat Oncol2022
35477748Radiotherapy on-chip: microfluidics for translational radiation oncology.Lab Chip2022
36087255Cell Death Analysis in Cancer Spheroids from a Microfluidic Device.Methods Mol Biol2022
33259935Quality of Life: A Prospective Randomized Trial of Palliative Volumetric Arc Therapy Versus 3-Dimensional Conventional Radiation Therapy.Int J Radiat Oncol Biol Phys2021
33494434Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells.Cancers (Basel)2021
33516789X-ray on chip: Quantifying therapeutic synergies between radiotherapy and anticancer drugs using soft tissue sarcoma tumor spheroids.Radiother Oncol2021
33885704Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.JAMA Oncol2021
34439199Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy.Cancers (Basel)2021
32033118Synergy between Non-Thermal Plasma with Radiation Therapy and Olaparib in a Panel of Breast Cancer Cell Lines.Cancers (Basel)2020
30642290Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.BMC Cancer2019
31673516Pathologic response after modern radiotherapy for non-small cell lung cancer.Transl Lung Cancer Res2019
30778138On-chip combined radiotherapy and chemotherapy testing on soft-tissue sarcoma spheroids to study cell death using flow cytometry and clonogenic assay.Sci Rep2019
30906663Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.Oncoimmunology2019
30380998Radiotherapy Immobilization Mask Molding Through the Use of 3D-Printed Head Models.Technol Cancer Res Treat2018
28779483Four PTEN-targeting co-expressed miRNAs and ACTN4- targeting miR-548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue.Int J Cancer2017
28409069Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report.Cureus2017
28428927Limitations of Personalized Medicine and Gene Assays for Breast Cancer.Cureus2017
29383293A Pilot Study in the Use of Activity Trackers for Assessing Response to Palliative Radiotherapy.Cureus2017
29234568Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery.Cureus2017
28976942Reconfigurable Microfluidic Magnetic Valve Arrays: Towards a Radiotherapy-Compatible Spheroid Culture Platform for the Combinatorial Screening of Cancer Therapies.Sensors (Basel)2017
26868346Prophylactic dexamethasone for radiation-induced bone-pain flare - Authors' reply.Lancet Oncol2016
27788956A Study of Pseudoprogression After Spine Stereotactic Body Radiation Therapy.Int J Radiat Oncol Biol Phys2016
27248467A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy.Oncotarget2016
26714494Molecular Predictors of Radiotherapy Response in Sarcoma.Curr Treat Options Oncol2016
25970788Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas.Oncotarget2015
26489389Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial.Lancet Oncol2015
25859829Soft tissue sarcoma and radiation therapy advances, impact on toxicity.Curr Treat Options Oncol2015
25854524Patterns of use and patient characteristics: brachytherapy for localized prostate cancer in octo- and nonagenarians.World J Urol2015
25880806Developing a prognostic micro-RNA signature for human cervical carcinoma.PLoS One2015
24764719Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy.Curr Oncol2014
25326640Combining targeted agents with modern radiotherapy in soft tissue sarcomas.J Natl Cancer Inst2014
24969789Radiogenomics: radiobiology enters the era of big data and team science.Int J Radiat Oncol Biol Phys2014
25150633Spatial and volumetric changes of retroperitoneal sarcomas during pre-operative radiotherapy.Radiother Oncol2014
23705661Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma.Radiat Oncol2013
21664063Ductal carcinoma in situ--the influence of the radiotherapy boost on local control.Int J Radiat Oncol Biol Phys2012
22670102Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study.Curr Oncol2012
22579375In regard to RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies: in regard to Wang et al (Int J Radiat Oncol Biol Phys 2011;81:e525-e528).Int J Radiat Oncol Biol Phys2012
20621425Use of three-dimensional ultrasound in the detection of breast tumor bed displacement during radiotherapy.Int J Radiat Oncol Biol Phys2011
20591518Dosimetric evolution of the breast electron boost target using 3D ultrasound imaging.Radiother Oncol2010
19219022Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.Nat Med2009
15867259Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells.Clin Cancer Res2005
12107849Cytostatic potential of novel agents that inhibit the regulation of intracellular pH.Br J Cancer2002
  • 1 - 45 of 45

Recommended Authors

Erqi L Pollom
Stanford University
Career Start Year 2014
Number of shared co-authors 2
Andrew Warner
Western University and London Regional Cancer Program
Career Start Year 2013
Number of shared co-authors 3
Soumyajit Roy
Rush University Medical Center
Career Start Year 2013
Number of shared co-authors 3
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Career Start Year 2012
Number of shared co-authors 2
Joseph Sia
Peter MacCallum Cancer Centre, University of Melbourne
Career Start Year 2011
Number of shared co-authors 1
Anusha Kalbasi
Stanford Cancer Institute, Stanford School of Medicine
Career Start Year 2010
Number of shared co-authors 1
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 1
Emmanouil Fokas
Universityhospital Frankfurt
Career Start Year 2007
Number of shared co-authors 2
Michael Xiang
University of California los angeles
Career Start Year 2007
Number of shared co-authors 2
Daniel J Ma
Mayo Clinic
Career Start Year 2005
Number of shared co-authors 2
Daniel S Higginson
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 4
Albert J Chang
University of California Los Angeles
Career Start Year 2003
Number of shared co-authors 2
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 2
Amit Bahl
University Hospitals Bristol and Weston NHS Foundation Trust
Career Start Year 2001
Number of shared co-authors 1
David A Palma
University of Western Ontario
Career Start Year 2000
Number of shared co-authors 5
Chandana A Reddy
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 3
Sana D Karam
University of Colorado School of Medicine
Career Start Year 2000
Number of shared co-authors 2
Chiaojung Jillian Tsai
Memorial Sloan Kettering Cancer Center
Career Start Year 2000
Number of shared co-authors 1
Steve E Braunstein
University of California san francisco
Career Start Year 1998
Number of shared co-authors 0
Phuoc T Tran
University of Maryland School of Medicine
Career Start Year 1996
Number of shared co-authors 3
Glenn Bauman
Western University and London Regional Cancer Program
Career Start Year 1994
Number of shared co-authors 6
Kevin Camphausen
National Cancer Institute
Career Start Year 1994
Number of shared co-authors 1
Philippe Lambin
Maastricht University
Career Start Year 1992
Number of shared co-authors 12
Theodore L DeWeese
Johns Hopkins University School of Medicine
Career Start Year 1991
Number of shared co-authors 4
William F Hartsell
Proton Therapy Center- Northwestern University
Career Start Year 1989
Number of shared co-authors 3
Ivy A Petersen
Mayo Clinic
Career Start Year 1989
Number of shared co-authors 5
Silvia C Formenti
Weill Cornell Medical College
Career Start Year 1986
Number of shared co-authors 1
Peter Hoskin
Mount Vernon Cancer Centre
Career Start Year 1985
Number of shared co-authors 7
Andrzej Niemierko
Massachusetts General Hospital
Career Start Year 1982
Number of shared co-authors 1
Andre Konski
Chester County Hospital
Career Start Year 1982
Number of shared co-authors 2

Collaborators

Fei-Fei Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 3
Rebecca A Gladdy
Mount Sinai Hospital
Co-authored papers 3
Brian O'Sullivan
Princess Margaret Cancer Centre/University Health Network, University of Toronto
Co-authored papers 3
Jeff P Bruce
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Michael Brundage
Cancer Centre of Southeastern Ontario
Co-authored papers 2
Angela B Y Hui
Stanford University
Co-authored papers 2
Michael Milosevic
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Tareck Ayad
Montreal Hospital
Co-authored papers 2
Jay S Wunder
University of Toronto
Co-authored papers 2
Anthony Fyles
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Keyue Ding
Queen's University
Co-authored papers 2
Edward Chow
University of Toronto
Co-authored papers 2
Wei Xu
Princess Margaret Cancer Centre
Co-authored papers 2
Shaoming Yin
Takeda Development Center Americas Inc.
Co-authored papers 1
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 1
Andre Dekker
Maastricht University Medical Centre
Co-authored papers 1
Daryl Waggott
Ontario Institute for Cancer Research
Co-authored papers 1
Catharine M L West
University of Manchester
Co-authored papers 1
Timothy R Rebbeck
Center for Cancer Equity and Engagement, Dana-Farber/Harvard Cancer Center
Co-authored papers 1
Christine How
Ontario Cancer Institute, University Health Network (UHN)
Co-authored papers 1
Fred Saad
University of Montreal Health Center
Co-authored papers 1
Dirk De Ruysscher
Maastro Clinic
Co-authored papers 1
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Co-authored papers 1
Thomas M Pisansky
Mayo Clinic
Co-authored papers 1
Rui Yan
University of Groningen, University Medical Center Groningen
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
David A Cooper
Co-authored papers 1
Blaise A Clarke
University of Toronto.
Co-authored papers 1
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 1
Irene L Andrulis
University of Toronto
Co-authored papers 1
Release 1.2